Analysis of Survival of Pediatric Patients with Leukemias and Lymphomas in the Oncological Context: Epidemiological Study in the State of São Paulo, Brazil, 2000-2022

Author:

Prates Pedro Emílio GomesORCID,Alonso Jonas Bodini,Carvalho Emília Campos de,Arcêncio Ricardo Alexandre,Zamarioli Cristina Mara

Abstract

Introduction: The time taken for screening, detection and initiation of treatment is a determining factor for therapeutic management in oncology. The availability of reliable data guides decisions for public policies and evaluates compliance with these policies. Objective: To analyze the survival and outcomes of pediatric patients with leukemia and lymphoma from 2000 to 2022. Method: Epidemiological, descriptive study, with data extracted from Fundação Oncocentro do Estado de São Paulo, according to the International Classification of Childhood Cancer (ICCC). The time elapsed between the first consultation and diagnosis was evaluated, between diagnosis and the start of oncological treatment, and the survival of these patients, calculated according to the Peto-Peto test. Results: 12,030 cases were analyzed, 6,994 in males and 7,292 with leukemia. The probability of the time between consultation and diagnosis exceeds 30 days was 49.29% for leukemias and 76.31 for lymphomas, a significant result for treatment and relapses (p < 0.001) but not in relation to sex; the time between diagnosis and treatment exceeding 60 days was 38.04% for leukemias and 71.97% for lymphomas. Not undergoing treatment was significant (p < 0.001) while waiting for diagnosis after consultation for patients with leukemia and lymphomas, except surgery, chemotherapy and radiotherapy combined. Conclusion: Despite the advances, a considerable percentage of patients wait longer than expected for diagnosis and initiation of treatment, impacting their survival rates.

Publisher

Revista Brasileira De Cancerologia (RBC)

Reference37 articles.

1. Erdmann F, Frederiksen L, Bonaventure A, et al. Childhood cancer: survival, treatment modalities, late effects and improvements over time. Cancer Epidemiol 2021;71(Part B):101733. doi: https://doi.org/10.1016/j.canep.2020.101733

2. Instituto Nacional de Câncer. Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro:INCA; 2023. [cited 2023 dez 1]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2023.pdf

3. Observatório de Oncologia [Internet]. Indicadores da Oncologia. São Paulo: Observatório de Oncologia; [date unknown]. [cited 2023 dez 25]. Disponível em: https://observatoriodeoncologia.com.br/indicadoresda-oncologia/

4. Wild CP, Weiderpass E, Stewart BW, editors. World cancer report: cancer research for cancer prevention [Internet]. Lyon (FR): International Agency for Research on Cancer; 2020. [cited 2022 july 3]. Available from: http://publications.iarc.fr/586

5. Maia F. Services assisted to the oncological patient within the framework of the single health-SUS system. Extramuros. 2019 [cited 2023 dez];7(1):86-107. Available from: https://www.periodicos.univasf.edu.br/index.php/extramuros/article/view/941

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3